Literature DB >> 12138285

Serum IgA/C3 ratio may predict diagnosis and prognostic grading in patients with IgA nephropathy.

Chizuru Ishiguro1, Yutaka Yaguchi, Kazuhiko Funabiki, Satoshi Horikoshi, Isao Shirato, Yasuhiko Tomino.   

Abstract

Recently, the authors reported that the ratio of serum IgA to C3 (serum IgA/C3 ratio) is a good marker to distinguish patients with IgA nephropathy from non-IgA nephropathy patients together with serum IgA levels using an international reference preparation (IFCC/CRM470). In this study, the authors investigated whether the serum IgA/C3 ratio might be an indicator of prognostic grading in patients with IgA nephropathy. Two hundred and thirteen patients with IgA nephropathy and 96 other glomerular diseases including diffuse or focal mesangial proliferative glomerulonephritis without mesangial IgA deposition (non-IgA PGN), membranous nephropathy and thin basement membrane syndrome were examined. The levels of serum IgA and C3 in these patients were adjusted by the specified formula to those using international standard serum (IFCC/CRM470) in this study. The results of this study showed the highest levels of IgA/C3 ratio in patients with IgA nephropathy. The serum IgA/C3 ratio appears to gradually increase according to the prognostic grading of this disease. Therefore, measurement of the serum IgA/C3 ratio may be useful for prediction of diagnosis and prognostic grading in patients with IgA nephropathy. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12138285     DOI: 10.1159/000065043

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  8 in total

Review 1.  Biomarkers in IgA nephropathy: relationship to pathogenetic hits.

Authors:  Margaret Colleen Hastings; Zina Moldoveanu; Hitoshi Suzuki; Francois Berthoux; Bruce A Julian; John T Sanders; Matthew B Renfrow; Jan Novak; Robert J Wyatt
Journal:  Expert Opin Med Diagn       Date:  2013-11

2.  How to take advantage of easily available biomarkers in patients with IgA nephropathy: IgA and C3 in serum and kidney biopsies.

Authors:  Małgorzata Mizerska-Wasiak
Journal:  Pediatr Nephrol       Date:  2022-08-02       Impact factor: 3.651

3.  A noninvasive artificial neural network model to predict IgA nephropathy risk in Chinese population.

Authors:  Jie Hou; Shaojie Fu; Xueyao Wang; Juan Liu; Zhonggao Xu
Journal:  Sci Rep       Date:  2022-05-18       Impact factor: 4.996

4.  Prediction of diagnosis of immunoglobulin A nephropathy prior to renal biopsy and correlation with urinary sediment findings and prognostic grading.

Authors:  Kazutaka Nakayama; Isao Ohsawa; Atsuko Maeda-Ohtani; Maki Murakoshi; Satoshi Horikoshi; Yasuhiko Tomino
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

5.  Significance of serum IgA levels and serum IgA/C3 ratio in diagnostic analysis of patients with IgA nephropathy.

Authors:  Atsuko Maeda; Tomohito Gohda; Kazuhiko Funabiki; Satoshi Horikoshi; Isao Shirato; Yasuhiko Tomino
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

6.  Serum under-O-glycosylated IgA1 level is not correlated with glomerular IgA deposition based upon heterogeneity in the composition of immune complexes in IgA nephropathy.

Authors:  Kenji Satake; Yoshio Shimizu; Yohei Sasaki; Hiroyuki Yanagawa; Hitoshi Suzuki; Yusuke Suzuki; Satoshi Horikoshi; Shinichiro Honda; Kazuko Shibuya; Akira Shibuya; Yasuhiko Tomino
Journal:  BMC Nephrol       Date:  2014-06-13       Impact factor: 2.388

7.  High serum IgA/C3 ratio better predicts a diagnosis of IgA nephropathy among primary glomerular nephropathy patients with proteinuria ≤ 1 g/d: an observational cross-sectional study.

Authors:  Wen-Yu Gong; Man Liu; Dan Luo; Fan-Na Liu; Liang-Hong Yin; Yuan-Qing Li; Jun Zhang; Hui Peng
Journal:  BMC Nephrol       Date:  2019-04-30       Impact factor: 2.388

Review 8.  Monitoring Immune Responses in IgA Nephropathy: Biomarkers to Guide Management.

Authors:  Haresh Selvaskandan; Sufang Shi; Sara Twaij; Chee Kay Cheung; Jonathan Barratt
Journal:  Front Immunol       Date:  2020-10-06       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.